Cohesity Identity Resilience Equips Organizations to Proactively Secure and Recover Identity-based Cyberattacks 

SINGAPORE, Sept. 18, 2025 /PRNewswire/ — Cohesity and Semperis today announced a new product, Cohesity Identity Resilience, powered by Semperis, to defend enterprises’ critical Identity infrastructure, including Microsoft Active Directory assets from cyberattacks. Now available for purchase from Cohesity, the solution is the strongest of its kind in the market, enabling companies to proactively harden defenses, recover rapidly, and conduct comprehensive post-attack forensic investigations. 

Active Directory is the central nervous system of most enterprise IT environments, managing authentication and access to critical systems, applications, and data. Active Directory’s crucial role within IT environments makes it a primary target for cybercriminals. When Active Directory is compromised, attackers can gain unrestricted access to IT resources, often resulting in ransomware infection, data theft, and prolonged business disruption.  

Cohesity Identity Resilience supports Active Directory protection and recovery across hybrid environments. The solution helps users protect and secure on-premises Active Directory and extends these safeguards to Microsoft Entra ID in the cloud. Organizations can protect and recover the source of authority for objects synchronized across their entire Active Directory and Entra ID identity landscape. 

“Identity Security is one of the key battlegrounds of cyberattacks for enterprises and governments. They need solutions that combine prevention, resilience, and recovery without adding complexity to their existing cyber resilience strategy,” said Sanjay Poonen, chief executive officer, Cohesity. “Cohesity Identity Resilience delivers a modern, proven approach that helps organizations protect the foundation of their digital operations, so they can recover quickly from even the most critical attacks on identity infrastructures and remain cyber resilient. We’re excited to partner with Semperis on this effort.” 

Cohesity Identity Resilience builds on Semperis’ proven expertise and technology in Active Directory protection and recovery, delivering automated, malware-free recovery capabilities that minimize downtime and ensure a clean, reliable path back to normal business operations. With Cohesity Identity Resilience, customers benefit from: 

• Proactive Active Directory hardening – Provides the ability to scan on-prem or hybrid Active Directory environments for hundreds of indicators of exposure (IOEs), see risk scores, apply remediation guidance, and identify and prioritize attack paths that bad actors could use to reach critical privileged assets (Tier 0).
• Secure, immutable backups with capability for cyber vaulting – Enables consistent backup and recovery workflows while providing isolation of AD backups.
• Rapid and secure recovery – Restores Active Directory forests after a cyberattack or catastrophic failure, ensuring minimal downtime.
• Specialized identity forensics and incident response capabilities – Cleanses the system of attacker artifacts, ensuring Active Directory is restored to a trusted environment.
• Comprehensive post-breach analysis – Offers comprehensive post-attack forensic support, including rapid assessments within defined incident windows, and validation of Active Directory integrity before restoring production systems.

“Active Directory compromises are devastating because they give attackers so many paths to take advantage of critical systems,” said Mickey Bresman, chief executive officer, Semperis. “By partnering with Cohesity, we’re integrating our industry-leading Active Directory technology with the broadly adopted Cohesity Data Cloud, ensuring the world’s largest global organizations have a trusted, streamlined path to protect against and recover from even the most sophisticated identity-based attacks.”

Cohesity Identity Resilience builds on the partnership between Cohesity and Semperis that began in 2024.

“Active Directory compromises often turn into prolonged business disruptions that are costly and difficult to contain,” said Scott Harrison, director, Hybrid Infrastructure Solutions, CDW. “With Cohesity Identity Resilience, powered by Semperis, we see a solution that directly addresses this gap—helping enterprises strengthen defenses, recover quickly, and maintain confidence in their core identity systems. It’s the kind of capability our customers have been asking for, and it represents an important step forward in building true cyber resilience.” 

More information about Cohesity Identify Resilience can be found here.  

Try the following free tools to test identity security posture: 

• Attack path analysis tool: Discover risky attack paths to Tier 0 assets.
• Identity security assessment: Identify security vulnerabilities across identity infrastructure.

About Cohesity 

Cohesity protects, secures, and provides insights into the world’s data. As the leader in AI-powered data security, Cohesity helps organizations strengthen resilience, accelerate recovery, and reduce IT costs. With Zero Trust security and advanced AI/ML, Cohesity Data Cloud is trusted by customers in more than 140 countries, including 70% of the Global 500. Cohesity is also backed by partners such as NVIDIA, Amazon, Google, IBM, Cisco, and HPE.  

Cohesity is certified as a Great Place to Work in multiple countries. Follow Cohesity on LinkedIn and visit www.cohesity.com to learn more. 

About Semperis  

Semperis protects critical enterprise identity services for security teams charged with defending hybrid and multi-cloud environments from cyberattacks, data breaches, and operational errors. Purpose-built for securing hybrid identity environments—including Active Directory, Entra ID, and Okta—Semperis’ AI-powered technology protects over 100 million identities from cyberattacks, data breaches, and operational errors. 

As part of its mission to be a force for good, Semperis offers a variety of cyber community resources, including the award-winning Hybrid Identity Protection (HIP) Conference, HIP Podcast, and free identity security tools Purple Knight and Forest Druid. Semperis is a privately owned, international company headquartered in Hoboken, New Jersey, supporting the world’s biggest brands and government agencies, with customers in more than 40 countries.  

Learn more: https://www.semperis.com 

Follow us: Blog / LinkedIn / X / Facebook / YouTube 

YANTAI, China, Sept. 18, 2025 /PRNewswire/ — RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an oral presentation at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. The meeting will be held from October 29 to November 1, 2025, local time, at the Hilton San Francisco Union Square in California, USA.

Oral Presentation Details

Presentation Title: Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study
Session: MGFA. This session, invited by the Myasthenia Gravis Foundation of America (MGFA) Medical and Scientific Advisory Committee (MSAC), features clinical and scientific experts sharing current and future peer-reviewed research findings on myasthenia gravis (MG).
Presentation Time: October 29, 2025, at 10:50 AM Pacific Standard Time (October 30, 1:50 AM Beijing Time).

Previously, at the 2025 American Academy of Neurology (AAN) Annual Meeting held in March this year, RemeGen presented the 24-week data from the Phase III study of telitacicept for myasthenia gravis. The results showed that 98.1% of patients achieved an improvement of ≥3 points in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and 87% of patients achieved an improvement of ≥5 points in the Quantitative Myasthenia Gravis (QMG) score. Among drugs that have completed Phase III clinical studies for generalized myasthenia gravis, telitacicept has demonstrated highest MG-ADL response rate. The complete 48-week data to be presented at the AANEM Annual Meeting should further highlight telitacicept’s potential to become a best-in-class therapy in the field of myasthenia gravis.

In June 2025, RemeGen out-licensed telitacicept to Vor Bio (Nasdaq: VOR) and Vor Bio is actively advancing the global multicenter Phase III clinical trial of telitacicept for generalized myasthenia gravis (gMG), with patient recruitment progressing smoothly in the United States, Europe, South America, and the Asia-Pacific region.

About Telitacicept

Telitacicept is the world’s first and first-in-class injectable recombinant B-lymphocyte stimulator (BLyS)/A proliferation-inducing ligand (APRIL) dual-target fusion protein developed by RemeGen. It simultaneously inhibits the binding of BLyS and APRIL cytokines to their receptors on B cells, preventing abnormal differentiation and maturation of B cells, thereby treating autoimmune diseases. Telitacicept has been approved in China for the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG).

About Vor Bio

Vor Bio is a clinical-stage biotechnology company committed to the treatment of autoimmune diseases. The company focuses on rapidly advancing the Phase III clinical development and commercialization of the novel dual-target fusion protein telitacicept to meet the needs of patients with autoimmune diseases worldwide. For more information, please visit www.vorbio.com.

About Generalized Myasthenia Gravis (gMG)

gMG is a rare, chronic autoimmune disorder that disrupts communication between nerves and muscles, leading to muscle weakness that can affect mobility, vision, swallowing, and breathing. The disease is antibody-mediated, primarily by autoantibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), which interfere with neuromuscular transmission. Despite various treatment options, many patients continue to suffer from refractory symptoms or significant side effects. There is a significant unmet clinical need for new therapies that offer long-lasting efficacy, safety, and convenience. Currently, there are approximately 90,000 gMG patients in the US, 140,000 in Europe, and 29,000 in Japan.

YANTAI, China, Sept. 18, 2025 /PRNewswire/ — As the global power industry faces growing energy demands, an accelerating energy transition, aging infrastructure, and workforce shortages, the need for innovative technologies to enhance operational visibility and reliability has become increasingly urgent.

From September 17^th to 20^th, at Electric & Power Indonesia, the largest power exhibition in ASEAN, Raythink Technology is presenting its thermal imaging inspection solutions at Booth A2-2616. The company demonstrates how its predictive maintenance solutions help power utilities and operators build smarter and more efficient operations—turning industry challenges into opportunities.

How Raythink Empowers Rapid Development in the Power Industry

With its diverse thermal imaging portfolio and advanced technologies, Raythink holds key advantages. Firstly, Raythink’s solutions span the entire power ecosystem—from generation to distribution—ensuring seamless integration and efficient processes throughout the energy supply chain.

Second, and most importantly, thermal imaging inspection allows power grid operators to detect potential failures before they occur. Take power generation as an example: Raythink’s fixed thermal cameras—such as the TN and AT series—enable 24/7 monitoring of critical equipment. With built-in temperature analysis and instant alerts, these devices allow rapid detection of abnormalities. Operators can conduct follow-up checks using Raythink handheld imagers, enabling a proactive maintenance approach that minimizes costly unplanned downtime, lowers manual intervention, and boosts operational efficiency.

In addition, the non-invasive nature of these inspections significantly enhances operational safety, as personnel can avoid direct exposure to hazardous live equipment.

Proven Success with Trusted Partners

Raythink’s solutions have gained recognition from clients worldwide, making it a trusted innovation partner in the energy sector.

Perusahaan Listrik Negara (PLN), the Indonesian state-owned electricity company that manages electricity generation, transmission, and distribution across Indonesia, is one of Raythink’s clients. “PLN has already purchased a significant number of IX2 AIR units for electricity inspections, and the results have been highly satisfactory,” noted Kevin Wang, the sales manager of Raythink.

These global partnerships are built on superior performance, full after-sales support, and ongoing upgrades—enabling safer grids and smarter maintenance through reliable thermal imaging inspection.

To experience these solutions firsthand, Raythink invites all Electric & Power Indonesia attendees to visit Booth No.A2-2616 for a live demonstration and technical consultation.

For more information:

Email: sales@raythink-tech.com 

Website: https://www.raythink-tech.com/ 

GUANGZHOU, China, Sept. 18, 2025 /PRNewswire/ — As global trade continues to evolve, China Foreign Trade Centre (CFTC), the organizer of China Import and Export Fair, also known as the Canton Fair, has launched Trade Bridge, an innovative project aimed to foster seamless, year-round matchmaking between global buyers and Chinese suppliers. Developed in partnership with the Canton Fair’s global network and industry leaders, Trade Bridge is designed to meet real-time sourcing needs through targeted matchmaking events.

Since its inception in 2021, Trade Bridge has become a flagship program of the Canton Fair’s ongoing trade promotion efforts. It has attracted buyers from more than 100 countries and regions, facilitating thousands of business negotiations. In 2024 alone, Trade Bridge hosted more than 700 matchmaking events, connecting 1,300 buyers with 3,400 suppliers and generating over $1 billion in intended orders.

Recent events have demonstrated the platform’s growing impact. In June, Trade Bridge brought 16 international buyers from the U.S., Mexico, the UAE, Morocco, and Hong Kong SAR to Zhejiang’s Pinghu City, an emerging hub for luggage and electric ride-on toys. Buyers visited eight local factories and held in-depth discussions with 50 suppliers, leading to intended deals valued at more than $28 million.

In July, Trade Bridge turned its focus to Dongguan, a manufacturing powerhouse in southern China. Over 20 leading buyers from Denmark, Germany, the U.S., Japan, and Australia engaged with more than 90 Dongguan-based enterprises across sectors including toys, furniture, and electronics. Participating buyers included top-tier retailers such as Japan’s NITORI and Denmark’s F&H Group.

Zhang Sihong, Deputy Director General of CFTC, noted that the event was designed to deliver concrete sourcing needs directly to enterprises, creating a streamlined pathway for accurate supply-demand matching. He emphasized that by removing information barriers and connecting companies more efficiently with global resources, the initiative opens new growth opportunities, smooths the path for Chinese products abroad, and injects momentum into stabilizing foreign trade.

These events are part of a broader strategy to make the Canton Fair everlasting for global trade. Looking ahead, the Canton Fair will continue to expand Trade Bridge activities, enhance its digital platform, and provide more efficient, targeted services to global buyers and Chinese suppliers, helping quality Chinese products reach the world with faster speed and higher precision.

For more information, please visit https://www.cantonfair.org.cn/en-US.

SHANGHAI, Sept. 18, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as a poster at the 22nd International Myeloma Society (“IMS”) Annual Meeting. The poster was titled “Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma” (Abstract number: PA-029).

In this study, a total of 14 patients with relapsed or refractory multiple myeloma (R/R MM) received a single infusion of zevor-cel. As of February 22, 2025, the median follow-up duration was 53.3 months (range:14.8, 63.5).

Regarding safety: There were no reports of ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy or other delayed AEs on the study.

Regarding efficacy: The overall response rate was 100% (95% CI: 76.8, 100.0) with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10⁻⁵ threshold. One patient remained in sCR at 59.3 months in the study. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (OS) was not reached. The proportion of patients surviving at 24, 36, 48 and 60 months after infusion were 100%, 92.3%, 84.6% and 76.9%, respectively.

At approximately 5 years of follow-up, zevor-cel demonstrates manageable safety profile while eliciting deep and durable responses in R/R MM patients.

About Zevor-cel

Zevor-cel is a fully human, autologous BCMA CAR T-cell product for the treatment of Multiple Myeloma (MM). Zevor-cel was approved by the NMPA on February 23, 2024 for the treatment of adult patients with R/R MM who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent). Zevor-cel received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

The GasHub-led conversion from diesel to LNG is estimated to decrease the carbon footprint of the production facility by approximately 30%.

SINGAPORE, Sept. 18, 2025 /PRNewswire/ — H2G Green Limited (SGX:5AI) (“H2G” or the “Company“, together with its subsidiaries, collectively the “Group“), one of the leading sustainable energy solutions providers, and its subsidiary GasHubUnited Utility Private Limited (“GasHub“) today announced the completion and commissioning of one of its largest liquefied natural gas (“LNG“) facilities to date, built for a leading food and beverage (“F&B“) manufacturer in Singapore.

GasHub has led the F&B manufacturer in transitioning its operations from diesel to LNG, retrofitting its current production site in Singapore. GasHub completed the retrofitting recently and made its first LNG delivery to prepare the facility to begin using LNG.

Designed, constructed, and commissioned by GasHub, the new LNG facility will substantially support the F&B manufacturer’s thermal energy needs for manufacturing consumer beverage products for regional markets.

“Industrial facilities represent a significant opportunity for Singapore to reduce emissions and strengthen energy security through switching to LNG,” said Bentinck Ng, CEO of GasHub. “Our partnership with this leading F&B manufacturer showcases how LNG can deliver various benefits. By replacing diesel, companies can significantly reduce carbon footprints and maintenance costs while benefiting from cleaner, more efficient operations. At the same time, this project highlights the unique, homegrown engineering expertise GasHub brings to Singapore’s industrial energy sector—a space often overlooked compared to power generation. If more companies follow, together we can accelerate progress toward a greener, more energy-secure Singapore.”

Driving efficiency and sustainability

The facility’s conversion to LNG will achieve significant benefits:

• Reduced emissions: The switch is estimated to lower the carbon footprint of the manufacturer’s production facility by approximately 30%.
• Cleaner operations: Unlike diesel, LNG combustion leaves no carbon residue, reducing maintenance requirements and improving boiler efficiency.
• Improved stability in energy cost: LNG provides an energy source with greater cost stability and long-term efficiency, helping to increase financial stability and predictability.
• Improved workplace environment: LNG combustion eliminates odour and potential contamination associated with diesel use.

With this transition, this F&B manufacturer is now one of the largest LNG users GasHub supplies to date.

Trusted by industry leaders

In addition to improving sustainability, GasHub was selected for the project due to its proven engineering expertise in designing, building, and maintaining LNG infrastructure for industrial clients.

About H2G Green Limited

H2G focuses on delivering sustainable energy solutions through its two subsidiaries: GasHub for LNG and Green Energy Investment Holding Private Limited for hydrogen, biochar, and other high-value, sustainable materials. In Singapore, the Company is working towards solving the energy trilemma — advancing cost competitiveness of sustainable energies, expanding energy security, and transitioning to net zero. Beyond Singapore, the Company is powering Southeast Asia’s transition towards cleaner, sustainable energy solutions. H2G stands out for deep engineering, energy, and sustainability expertise and an unwavering commitment to safety.

For more information, please visit: https://h2g.green.

– CEO Choi recognized for her leadership in global dialogues and cooperation to advance safe AI development and establish a digital ecosystem

– Sanda Ojiambo, CEO and Executive Director of the UN Global Compact, said, “CEO Choi Soo-yeon’s global leadership and deep expertise will be a great asset in achieving the UN Global Compact ‘s goals.”

SEONGNAM, South Korea, Sept. 18, 2025 /PRNewswire/ — NAVER Corporation (CEO Choi Soo-yeon) announced on September 18 (local time) that CEO Choi has been officially appointed as a new member of the Board of Directors of the United Nations Global Compact. This appointment recognizes her contribution in taking a leading role in international discussions to establish a safe AI ecosystem. As a board member, CEO Choi will serve a three-year term, actively participating in regular board meetings and key UN Global Compact activities.

The UN Global Compact is the world’s largest voluntary corporate citizenship initiative, with more than 25,000 companies and organizations across 167 countries. Established in July 2000, it presents ten principles in the four key areas of human rights, labor, environment, and anti-corruption, supporting companies in practicing responsible management for sustainable growth. In Korea, 360 companies in the private sector are participating in the UN Global Compact.

The UN Global Compact recognized CEO Choi’s leadership in spearheading international cooperation and dialogue on “AI governance,” aimed at establishing ethical and responsible principles throughout the full cycle of AI technology development. At the AI Action Summit held in Paris in February this year, she joined global leaders to discuss the future direction of AI development and outlined NAVER’s vision for securing diversity within the digital ecosystem through AI. In June 2024, NAVER introduced the AI Safety Framework (ASF), a comprehensive approach to identifying and managing potential risks across all stages of AI systems.  

The UN Global Compact also commended CEO Choi for establishing NAVER Ventures in Silicon Valley, where she has built a collaborative ecosystem by identifying and supporting promising startups across diverse nationalities and sectors. In addition, through the launch of NAVER Impact in 2024, CEO Choi has consistently emphasized sustainable growth in partnership with local communities, SMEs, and startups.

Sanda Ojiambo, CEO & Executive Director of the UN Global Compact, announced, “Choi Soo-yeon brings deep expertise on how digital companies can create value and scale globally while upholding principles on responsible and sustainable business. We look forward to her participation on our Board as we mobilize business to deliver the Sustainable Development Goals (SDGs).”

Lee Dong-Kurn, President of the UN Global Compact Network Korea, stated, “We are delighted that CEO Choi Soo-yeon has been appointed as a UN Global Compact board member, the first Korean in 17 years. We look forward to NAVER continuing to lead the establishment of a sustainable management ecosystem on the global stage and to playing an active role as a global leader through ongoing collaboration with the UN Global Compact.”

Following her appointment, CEO Choi will attend the upcoming UN Global Compact Board meeting at the UN Headquarters in New York on September 20 (U.S. local time). As a newly appointed board member, she is expected to actively participate in transnational discussions on establishing ethical AI governance on the global stage.

About NAVER

Founded in 1999, NAVER is Korea’s largest Internet company and one of the world’s top tech companies. Leading cutting-edge technologies, NAVER operates No.1 search engine in Korea and holds various business portfolios encompassing commerce, fintech, cloud, AI and robotics.

NAVER recorded sales of KRW 10.74 trillion (USD 7.5 billion) in 2024. TEAM NAVER continues to enhance its business portfolio and expand its global presence across Japan, North America, and Europe, while pursuing innovation through continuous research and development in future technologies.

To learn more, visit www.navercorp.com/en